Daily Archives: June 3, 2022

Doctor Robert Willan was the first to accurately describe the different types of psoriasis in the early 1800s. In the early 1960s, experts found that psoriasis was an autoimmune disorder, and modern treatment began in the mid-1900s.

In 1809, the English doctor Robert Willan was the first to develop an accurate description of the different types of psoriasis. While doctors learned more about the condition over the years, a pivotal finding emerged in 1963, when E. J. Van Scott found that psoriasis was an autoimmune disorder.

Modern treatment for this condition became available in the mid-1900s, and doctors still use these treatments today. Options include ultraviolet light and medications to reduce inflammation and suppress the immune system.

This article discusses the history and discovery of psoriasis and how treatment has changed.

According to the Psoriasis and Psoriatic Arthritis Alliance, people were aware of psoriasis as early as ancient Greece. Hippocrates wrote some of the first descriptions of skin conditions. However, he classified psoriasis in the same category as leprosy (Hansens disease).

People continued to classify psoriasis in the same category as Hansens disease for several centuries, and as a result, people with psoriasis often experienced stigma and were outcasts from society.

During the Renaissance period, several people wrote books further categorizing skin conditions. Two Italian authors, Girolamo Mercuriale and Bernardino Ramazzini, began to describe different skin conditions, including psoriasis, in their books De Morbius Cutaneis and De Morbis Artificum.

In 1809, the English doctor Robert Willan also categorized skin conditions. He was the first person to provide a description of different types of psoriasis, and he wrote about the progression of the condition.

While Robert Willan was the first person to investigate psoriasis as a separate condition, he still used the term lepra vulgaris, which contributed to people associating psoriasis with leprosy.

In the 1800s, the Austrian physician Ferdinand von Hebra was the first to use modern research techniques to study skin conditions. He also removed lepra from the description of psoriasis.

During this century, French doctors discovered the connection between psoriasis and a form of arthritis called psoriatic arthritis.

Other medical professionals of the time continued to make discoveries that led to later research subcategorizing psoriasis. For example, Australian dermatologist William J. Munro discovered mico-abscesses in the top layer of the skin in people with this condition. Later research would find that these abscesses are part of psoriasis vulgaris, a common form of this condition.

Heinrich Kbner made an important discovery during the 19th century. He found that people with psoriasis may also develop psoriatic lesions in previously unaffected areas that have experienced trauma, such as a cut, burn, or bruise. Doctors still use the Kbner phenomenon as a diagnostic tool today.

The 20th century saw various advancements in the classification of psoriasis and its symptoms.

In 1910, Leo von Zumbusch was the first to describe pustular psoriasis, a rare type of psoriasis that causes pustules, blisters, fever, and fatigue.

In 1926, Dr. Woronoff discovered that people with psoriasis may have a pale ring of skin around healing lesions. This halo, or Woronoff ring, is another diagnostic tool that medical professionals use. The appearance of a Woronoff ring may be a sign that psoriasis lesions are healing.

In 1963, E. J. Van Scott found that people with psoriasis have a rapid turnover of cells, which is a marker of an autoimmune condition. This discovery that psoriasis is an autoimmune condition affected the way doctors treated this condition.

A 1973 paper by John M. Moll and Verna Wright linked psoriasis to psoriatic arthritis. This was one of the first research papers to distinguish psoriatic arthritis from rheumatoid arthritis.

The understanding that psoriasis is an autoinflammatory condition rather than a skin disease has led to advances in treatment. In auto-inflammatory conditions, the immune system attacks healthy tissue and cells in the body.

Within the last decade, discoveries in genetics and molecular science have led to a greater understanding of how psoriasis affects people. Researchers now know that the cause is a complex interaction between immunological, environmental, cellular, and genetic factors.

One of the earliest treatments for psoriasis was coal tar. Medical professionals may still recommend using coal tar as a first-line treatment in cases of mild plaque psoriasis. And they may recommend it in combination with other medications for cases of moderate or severe plaque psoriasis.

In the 1920s, William Goeckerman developed Goeckerman therapy, which combined UVB light with coal tar to treat psoriasis. Doctors still use this treatment today for moderate or severe psoriasis.

Throughout the 1900s, experts created several new treatments, such as:

Biologic drugs are the most recent development in the treatment of psoriasis. These drugs interrupt the immune process of the condition, which can help ease its symptoms. A 2018 study reports that biologics are highly effective and lead to dramatic improvements in 8090% of people with psoriasis.

Healthcare professionals may also prescribe topical and oral retinoids, such as acitretin (Soriatane). Experts are also investigating the effectiveness of Janus kinase (JAK) inhibitors, which healthcare professionals already use in the treatment of rheumatoid arthritis and psoriatic arthritis.

People have been aware of psoriasis for centuries and often grouped this condition with leprosy (Hansens disease). Over time, experts began to recategorize this condition and learn more about how it affects the body, eventually discovering it is an autoimmune condition.

Similarly, treatment has evolved over time to become more effective. There are now several options that a doctor may recommend, many of which were first discovered in the 1900s.

Excerpt from:
The discovery and history of psoriasis: What to know - Medical News Today

Psoriasis can cause stress for someone with the condition due to difficulties managing symptoms, physical discomfort, or feelings of social embarrassment. Conversely, stress can also trigger psoriasis flares. Practicing self-care to improve mental health and reduce stress can help to reduce the chance of stress triggering further flares.

Psoriasis and stress share a symbiotic relationship of sorts, where each can cause and worsen the symptoms of the other.

Psoriasis is a type of immune-mediated disease where the immune system causes inflammation throughout the body.

While many people may associate the condition with scaly patches of skin, it can also cause issues in other areas of the body.

In addition, living with psoriasis can also affect a persons mental health. It may cause a person to feel stress relating to showing their skin, social situations, or caring for the condition.

Stress can then trigger a psoriasis flare or a worsening of symptoms. As a result, people living with psoriasis often benefit from managing both their physical and mental health.

Psoriasis can cause stress, and stress can cause psoriasis symptoms to worsen.

A 2018 review of studies looking at the link between psoriasis and stress notes that anywhere from 3188% of people living with psoriasis report stress as a trigger for their symptoms.

It also noted that, in addition to triggering flares, stress may also trigger the development of the condition itself in people predisposed to developing psoriasis.

How stress influences psoriasis is still not fully understood. According to an older study, one hypothesis, called the neurogenic inflammation hypothesis, states that psoriasis causes the release of neuropeptides, such as substance P (SP) and nerve growth factor (NGF).

These substances then cause local inflammation and result in the formation of psoriasis plaques. The hypothesis notes that stress releases high amounts of SP, which could then trigger the onset of the condition or flares.

When psoriasis plaques occur, it can cause stress for the person. The stress may relate to issues of embarrassment, the challenges of dealing with symptoms, discomfort, or a combination of different emotions.

The National Psoriasis Foundation recommends that all people living with psoriasis take steps to manage their stress as part of their treatment plan. They recommend a person:

According to a 2019 study, there is a link between alcohol intake and an increase in anxiety and depression. Therefore, a person may consider limiting their alcohol consumption to help minimize stress.

Before starting any new exercise programs, a person should talk with a doctor about what activities will be safe for them to perform.

Psoriasis is a lifelong condition characterized by periods of flares and remission. When treating psoriasis, a doctor will often suggest a combination of medications, therapies, mental health support, and lifestyle changes to help keep the condition under control.

Medical treatments may include:

Doctors may also recommend lifestyle changes that help manage symptoms and triggers. The American Academy of Dermatology Association (AAD) recommends a person take some steps to help manage their psoriasis at home:

In addition, a person should take measures to learn and avoid triggers. Triggers can vary from person to person but can include stress and weather changes.

By managing stress, a person may be able to help reduce psoriasis flares.

A person can consider the following general tips for managing stress, including:

Psoriasis triggers can vary from person to person. It is important for an individual to understand their triggers so that they can take steps to avoid them.

Some common triggers of psoriasis include:

Psoriasis and stress share a link both conditions can trigger the other.

Mental health treatment, including lifestyle changes such as physical exercise, can help prevent stress from triggering flares.

It can also help a person cope with the stress and other emotions that often accompany living with psoriasis.

See more here:
Psoriasis and stress: The relationship and how to break the cycle - Medical News Today

Health Policy and Law Daily

2022 JUN 02 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Current study results on psoriatic arthritis have been published. According to news reporting out of Boston, Massachusetts, by NewsRx editors, research stated, Specialty medications provide effective treatment with limited adverse effects to patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment for patients with commercial health insurance.

The news journalists obtained a quote from the research from Tufts Medical Center: We aimed to evaluate coverage of psoriasis and psoriatic arthritis specialty medications by commercial insurance companies. We compiled data regarding specialty drug coverage for psoriasis and psoriatic arthritis using Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database and analyzed the data for any notable trends. The SPEC database lists coverage decisions for 158 specialty drugs by 17 of the largest US commercial health plans, as well as data regarding the types of evidence cited by these insurance plans when making coverage decisions. Our results showed that insurance plans tend to be more restrictive than the U.S. Food and Drug Association (FDA) label when covering medications for psoriasis and psoriatic arthritis. Furthermore, medications for psoriatic arthritis tended to be less restricted than for psoriasis, and medications were most commonly approved as second line agents for both indications.

According to the news reporters, the research concluded: Our analysis confirms that variability in insurance coverage exists for the indications of psoriasis and psoriatic arthritis.

For more information on this research see: Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. Journal of Psoriasis and Psoriatic Arthritis, 2022. The publisher for Journal of Psoriasis and Psoriatic Arthritis is SAGE Publications.

A free version of this journal article is available at https://doi.org/10.1177/24755303221101843.

Our news editors report that additional information may be obtained by contacting Christine Learned, Department of Dermatology, Tufts Medical Center, Boston, MA, United States. Additional authors for this research include Sara Alsukait, Kristin R Fiumara, Melissa Ortega, James D Chambers, David Rosmarin.

ORCID is an identifier for authors and includes bibliographic information. The following is ORCID information for the author of this research: David Rosmarin (http://orcid.org/0000-0003-2786-0708).

(Our reports deliver fact-based news of research and discoveries from around the world.)

The rest is here:
Findings from Tufts Medical Center in Psoriatic Arthritis Reported (Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial...

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis

Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class

Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition's potential for transformative efficacy across many disease states

LOS ANGELES and SOLNA, Sweden, and SHANGHAI, June 3, 2022 /PRNewswire/ -- ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals today announced data from a 16-week, global, Phase 2 clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) presented by Frank Behrens, MD, Associate Professor of Medicine, Head of Rheumatology Clinical Research, University Hospital & Deputy Director Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Goethe-University Frankfurt, Germany and a founding member of the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), during a podium session at the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress in Copenhagen.

The randomized double-blind, placebo-controlled, Phase 2 clinical trial evaluated the safety and efficacy of izokibep dosed 80 mg every two weeks (Q2W) or 40 mg Q2W, versus placebo Q2W, in adult patients with active PsA. The global study assessed various endpoints at 16 weeks including the American College of Rheumatology (ACR) response, the Leeds Enthesitis Index (LEI), the Psoriasis Area and Severity Index (PASI) score and Quality of Life via the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire.

Endpoint

Placebo

Izokibep 80 mg Q2W

Izokibep 40 mg Q2W

ACR50

p-value

13%

52%

0.0006

48%

0.0014

Leeds Enthesitis1

(% LEI=0)

p-value for means

10%

88%

0.0003

63%

0.0095

PASI752

p-value

14%

85%

<0.0001

83%

<0.0001

PsAID

(% beyond MCID)

p-value

12%

41%

0.0017

31%

0.0418

1FAS, observed data for LEI > 0 at baseline N=43 (32%) post-hoc analysis2FAS, observed data for psoriasis BSA 3% at baseline N=74 (55%) post-hoc analysis

Story continues

"Psoriatic arthritis is a painful and debilitating inflammatory disease of the peripheral joints, skin, and nails, and it can also affect the spine," said Professor Behrens. "Furthermore, residual entheseal pain and inflammation,which occurs in up to 60% of patients, is associated with more severe disease, poorer quality of life and is considered one of the most significant unmet needs of psoriatic arthritis patients. The data presented at EULAR demonstrate there is potential opportunity for increased therapeutic efficacy in joints, entheseal pain and inflammation resolution and improved quality of life, all of which would be meaningful for patients living with psoriatic arthritis."

Izokibep was well-tolerated in the study, having a favorable safety profile consistent with that previously observed for izokibep and the IL-17A inhibitor therapeutic class. The most commonly reported AEs were injection site reaction and injection site erythema, the majority of which was mild.

"The improvements demonstrated in arthritis, psoriasis and enthesitis are exciting relative to responses reported for the current standard of care," observed Professor Peter Taylor, Norman Collison chair of musculoskeletal sciences at the University of Oxford. "Combined with theclinically meaningful improvement in disease-specific quality of life and well-tolerated safety profile, izokibep seemspromising for patients living with the painful and debilitating symptoms of psoriatic arthritis, and I am eager to see its continued development for patients."

ACELYRIN holds worldwide rights to izokibep except development and commercialization rights by Inmagene in selected Asian countries, including China, Hong Kong, South Korea, and Taiwan, and excluding Japan. Affibody holds commercialization rights in the Nordic countries.

About izokibep

To date, more than 300 patients many for up to three years have received izokibep, a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies. With high potency and small molecular size, izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies require IV administration to achieve. Additionally, the small size of izokibep about one tenth the size of a monoclonal antibody enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory musculoskeletal condition affecting the peripheral joints, the skin (with psoriasis), the nails, and in approximately 30 percent of individuals, the spine. Left under-treated, PsA leads to chronic joint pain, swelling, and damage with a high potential for permanent disability. Psoriatic arthritis pathology is dominated by pro-inflammatory T-helper (Th-17) cells that lead to over expression of IL-17, IL-23, and TNF cytokines.

About ACELYRIN

ACELYRIN, INC. is a Los Angeles area-based biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. For more information, please visit http://www.acelyrin.com

About Affibody AB

Affibody AB is a clinical-stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody molecules and Albumod. Affibody is a holding of Patricia Industries. For more information, please visit http://www.affibody.com

About Inmagene Biopharmaceuticals

Inmagene Biopharmaceuticals, with wholly owned subsidiaries in San Diego, Shanghai, Hangzhou, and Wuhan, is a leading biotech company focused on immunology-related therapeutic areas. Believing in "borderless innovation", the Inmagene team integrates efficient resources worldwide to develop drugs for patients globally. Inmagene is operating twelve "Smart Innovation" programs to create and develop novel drug candidates for the global market. For more information, please visit http://www.inmagenebio.com

Disclaimer

This press release contains forward-looking statements. While ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by numerous hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Cision

View original content:https://www.prnewswire.com/news-releases/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-data-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-presented-during-2022-european-alliance-of-associations-for-rheumatology-congress-301560613.html

SOURCE ACELYRIN, INC.

Original post:
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis...

FANS of Kim Kardashian have long debated why the reality star is so often spotted covering her hands with various types of gloves when she goes out.

Now, they may have their answer, as the SKIMS founder was recently snapped with her hands bare, which appeared old and wrinkled.

5

5

In a series of new pictures, Kim was seen exiting a car. As she braced herself with her left hand, photos revealed her thin and bony frame.

On Reddit, fans were shocked by what they saw.

"Her skin looks like paper!" one fan exclaimed, as another added: "Where are the gloves when you need'em?!"

Still, one pointed out: "Hands tend to show age first, but she is also thin which lends itself to more visible blood vessels and tendons."

And another pointed out: "Doesnt she have psoriasis? Topical corticosteroids can cause the skin to become thin and age quickly."

Indeed, the 41-year-old has been open about herbattle with psoriasis, a skin disease that causes red, itchy, scaly patches.

The flare-ups most commonly occur on the knees, elbows, trunk, and scalp.

TheKeeping Up With the Kardashiansalum revealed she first began to deal with psoriasis in her mid-20s.

In an article for her sisterKourtneysbrandPoosh, Kim wrote: When I was 25, I had my first psoriasis flare-up.

I got a common cold, and since psoriasis is an autoimmune condition, this triggered it. It was all over my stomach and legs.

She continued: "Luckily, in my apartment complex at the time, my neighbor was a dermatologist. I showed it to him, and he said to come into the office, and he would give me a shot of cortisone, and then hopefully, it would go away (since it was my first big outbreak).

"I did this, and my psoriasis completely went away for about five years.

KardashianmatriarchKris Jenner, 66, also has psoriasis, though Kim was her only child to inherit the condition.

Kim explained in the Poosh story that her psoriasis returned when she was in her early 30s.

The model is currently celebrating the release of her newhigh-end skincare linecalled SKKN.

As part of the launch, she has admitted that her beauty "is not natural" and would take hours of work each morning, including stem cell facials and lasers.

In an interview with the New York Times, The Kardashiansstar explained she has a nine-step system that "might seem scary to some."

She added: "Thats why Im here to break it down, to be like, Theyre all necessary."

The Hulu star then dived into her appearance and revealed: "So many people want to act like they dont care about how they look.

"Im not acting like it comes easier or its all-natural. You just dont wake up and use whatever. You wake up, you use ingredients.

While using her SKKN samples, theKeeping Up With the Kardashiansalum demonstrated her lengthy routine.

She headed off to the bathroom and washed her face to remove the makeup from a previous photo shoot.

As part of her skincare routine, Kim cleansed, exfoliated, and patted her face with a combination of glow oil and face cream.

She concluded: I always go down to my chest - down to my nipples always down to nips.

5

5

5

We pay for your stories!

Do you have a story for The US Sun team?

Read this article:
Kim Kardashian fans shocked after they see what her hands really look like in new pics... - The US Sun

Artificial intelligence (AI) tool can drastically reduce diagnostic time for psoriatic arthritis patients, welcomes the educated community in a press release.

Its primarily dermatologists who treat patients with psoriasis and we have the opportunity to ask them about potential joint pain because about 10% of them may have osteoarthritis but without knowing it, recalls lead author Dr. Jonathan Shapiro of McCabe Health Services. The statement was quoted by Ramat Hasharon.

Since patients do not always associate joint pain with skin problems, they will talk to their general practitioner or orthopedic surgeon. But the latter can miss a psoriatic arthritis diagnosis because these symptoms are not very specific, leading to delayed care and risks of irreversible lesions and disability, he continues.

In this retrospective study, Dr. Shapiro and colleagues discover ways to recognize early

To access the rest of the article, you must accept performance and tracking cookies. It allows us to anonymously aggregate statistics that we share with our advertisers. Thanks to advertising, this site is funded and the articles written by our journalists are available to you for free.

To change your cookie settings, Press here.

Did you like this article?

Subscribe to our newsletter and receive weekly digital news from the health industries

Subtly charming problem solver. Extreme tv enthusiast. Web scholar. Evil beer expert. Music nerd. Food junkie.

Go here to see the original:
Artificial intelligence could shorten the diagnosis of psoriatic arthritis - Vaughan Today